OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
March 31, 2020
SAN FRANCISCO, CA– OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, has paused new patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D) in response to the COVID-19 pandemic.
Frank J. Steinberg, D.O., Head of Medical Oversight and founding Chief Medical Officer at OrphoMed, notified study sites through the contract research organization PPD® that screening should be temporarily stopped as of the end of business Friday, March 27, 2020.
“Our goal is to ensure that patient safety, as well as the safety of PPD® and site personnel, is not jeopardized,” Dr. Steinberg stated. “We hope that current ‘shelter in place’ practices in much of the country will decrease the spread of the coronavirus and will lead to a much improved situation and the resumption of study enrollment. In the meantime, we will work diligently to continue the study as planned for all patients currently enrolled to ensure their safety and the integrity of study data.”
About OrphoMed, Inc.
OrphoMed is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class dimer therapeutics. Leveraging its proprietary dimer platform technology engineered by founder Nikhilesh Singh, Ph.D., OrphoMed is advancing ORP-101 and a pipeline of additional dimer conjugates. In May 2017, OrphoMed completed a $39 million Series A financing with New Enterprise Associates, Takeda Ventures, Pappas Capital and Relativity Healthcare. For more information please visit www.orphomed.com.
This press release contains “forward-looking statements,” which reflect our current views and expectations with respect to future outcomes or events. When used in this press release, the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Because these statements are based on current estimates and assumptions, they are inherently subject to risks that could cause the actual outcomes to differ materially from what we currently expect. These forward-looking statements are subject to numerous risks and uncertainties, including, among others, the facts that we are substantially dependent on our ability to successfully develop and commercialize our products; the commercial adoption of our products and any other product candidates we develop will depend on the degree of their market acceptance; we have only limited assets and will need to raise additional capital before we can expect to generate revenue or become profitable; and we have never generated any revenue and may never be profitable. Forward-looking statements in this presentation apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.